(-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer

Figure 1 (-)-Epigallocatechin-3-gallate inhibits vascular endothelial growth factor production induced by interleukin-6 in human gastric cancer cells. A: When treated with (-)-Epigallocatechin-3-gallate (EGCG), vascular endothelial growth factor (VEGF) expression was dose-dependently decreased; B: Enzyme-linked immunosorbent assay showed that interleukin-6 (IL-6) induced VEGF secretion in human gastric cancer (AGS) cells and a 2.8-fold increase was observed. EGCG treatment dose-dependently reduced VEGF protein level in the conditioned medium. C: IL-6 also induced VEGF mRNA expression and a 3.1-fold increase in VEGF mRNA expression was observed. When treated with EGCG, VEGF mRNA expression was dose-dependently decreased. Values are expressed as percent of control (means ± SE, n = 3, ^aP < 0.05, ^bP < 0.01).